KTTA

0.58

0.07% -0.0004

Handel nachbörslich: .57 -0.01 -1.72%

Pasithea Therapeutics Corp (KTTA)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Schlusskurs vom Vortag:

$0.5804

Offen:

$0.5804

24-Stunden-Volumen:

222.70K

Relative Volume:

0.33

Marktkapitalisierung:

$19.38M

Einnahmen:

Nettoeinkommen (Verlust:

$-19.73M

KGV:

-0.2796

EPS:

-2.0742

Netto-Cashflow:

$-16.94M

1W Leistung:

+3.57%

1M Leistung:

+26.09%

6M Leistung:

-29.27%

1J Leistung:

-27.14%

1-Tages-Spanne:

$0.57

$0.5926

1-Wochen-Bereich:

$0.55

$0.595

52-Wochen-Spanne:

$0.281

$2.06

Pasithea Therapeutics Corp Stock (KTTA) Company Profile

Firmenname

Pasithea Therapeutics Corp

Sektor

Healthcare (1074)

Branche

Biotechnology (600)

Telefon

(702) 514-4174

Adresse

1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-08-13

Neueste SEC-Einreichungen

KTTA's Discussions on Twitter

Compare KTTA vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
KTTA Pasithea Therapeutics Corp	0.58	15.70M	0	-19.73M	-16.94M	-2.0742
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Pasithea Therapeutics Corp Aktie (KTTA) Neueste Nachrichten

Sep 03, 2026

Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences - GlobeNewswire

Sep 03, 2026

Aug 28, 2026

Enterprise value to revenue forward of Pasithea Therapeutics Corp. – NASDAQ:KTTAW - TradingView

Aug 28, 2026

Aug 21, 2026

Pasithea Therapeutics Receives Nasdaq Extension on Listing Compliance - TipRanks

Aug 21, 2026

Pasithea Therapeutics Received Notice of Noncompliance - TradingView

Aug 21, 2026

Pasithea (NASDAQ: KTTA) gets Nasdaq reprieve before possible delisting - Stock Titan

Aug 21, 2026

Aug 19, 2026

Pasithea (KTTA) Q1 2026 Earnings: EPS Clears the Reported Estimate; Session Move: The Stock Ends Down 1.21% in the Latest ReadingLow Growth Earnings - Vinanet

Aug 19, 2026

Aug 14, 2026

Pasithea Therapeutics Company Profile & Introduction - Moomoo

Aug 14, 2026

Pasithea Therapeutics Corp reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 14, 2026

Pasithea Therapeutics Corp. Q2 2026: Net loss $(5.27M), EPS $(0.16) — 10-Q Summary - TradingView

Aug 14, 2026

KTTA: Q2 2026 net loss rose to $5.27M as R&D spending surged; cash reserves at $45.7M - TradingView

Aug 14, 2026

Vivo Opportunity entities disclose 9.99% Pasithea Therapeutics (KTTA) holdings via warrants and stock - Stock Titan

Aug 14, 2026

Aug 11, 2026

Enterprise value to EBIT forward of Pasithea Therapeutics Corp. – NASDAQ:KTTAW - TradingView

Aug 11, 2026

Aug 10, 2026

Pasithea Therapeutics Corp expected to post a loss of 16 cents a shareEarnings Preview - TradingView

Aug 10, 2026

Aug 08, 2026

Pasithea Therapeutics (KTTA) Jumps 14% as Price Approaches Key ResistanceMotive Wave - dars.gov.et

Aug 08, 2026

Aug 07, 2026

Pasithea Therapeutics Corp. SEC Filing (Aug 7, 2026) - Stock Titan

Aug 07, 2026

Aug 05, 2026

Pasithea Therapeutics Corp. Revenue Breakdown – BOATS:KTTAW - TradingView

Aug 05, 2026

Aug 01, 2026

Pasithea Therapeutics (KTTA) Edges Higher: Micro-Cap Biotech Approaches Key Resistance at $0.48TRIN Signal - vinanet.vn

Aug 01, 2026

Jul 31, 2026

Opaleye group (NASDAQ: KTTA) discloses 6.14% Pasithea Therapeutics ownership in 13G/A - stocktitan.net

Jul 31, 2026

Jul 29, 2026

Pasithea Therapeutics (NASDAQ: KTTA) sets virtual 2026 meeting and reverse split vote - Stock Titan

Jul 29, 2026

Jul 28, 2026